Saw a one-line tweet the other day mentioning McColls #MCLS as one of 2 highest conviction names.

I think I see why: there's a metamorphosis happening underneath and reasonable path to PE and FCF multiples between 2-3 plus a growth narrative, all under that lovely grim exterior
Story is that they're shrinking. 1500+ stores 2 years back, to 1050 by the end of FY21

Also changing: culling small newsagent shops to focus towards larger, more profitable grocery-heavy stores. So far, so worthy - but the real interest is the transformation into Morrisons Daily
Company raised recently to accelerate a programme converting 350 stores into these Mini Morrisons. They're at 56 today, will be 350 by end FY22

Cost is £90K per shop, what they call "cash payback" is 2-3 years and so far they're providing pretty immediate LFL sales growth of 25%
TLDR: model out the stores with and without Morrisons, give it a couple of years for the payback time to bed in and it's an annual Δ of ~£180m-£200m in revs. Low 20s GMs, into a (*very*) roughly breakeven cost base gives +£40M, ¼ off for tax and voilà: £30m on a £55m cap, PE <2
FCFs something like this, 6 monthly. Idea being somewhere north of £20M yearly before long. We're currently in between the two marked points. I stopped modelling conversions at 350 but the co has another 400 odd that they reckon are suitable and the mood music suggests it happens
That's pretty much it, the rest here is just a few bits around assumptions I've made.

Offending tweet that sent me down the rabbit hole is below and a bit of back and forth in the DMs with @here_there (whose idea it is) helped me out. Worth a follow.

So, for the details. This horrific wall of numbers is to get one thing: revenues. Company says the top 500 stores do 50% of revenues. I split that out and assume they convert those first. My only real input is rev per store.
I take the high end of recent perf in top 500, put an immediate +25% of those going into Morrisons and matured them both at +1.5% per half (a guess, I don't know how these things mature) For the rump McColls, +1% to reflect getting rid of the worst stores.
The last 3x 6M of MCLS' results. I remove all their one time adjust's (invariably recurring, esp given the turnover in the store base), add but mainly subtract a few genuine one-timers, for a stab at a normalised cost base.

And as God intended add back leases where they belong,
Stick the whole unholy lot together and it ends up like this. Not a single number in here will be right, it's full of false precision, off timings because I average stores, assumptions aren't wildly blue sky but towards the favourable side. It's just to see what may be there.
From this lot, just want to highlight 2 things. First is the EBITDA line. I came at this from top down - interestingly to me is that if taking what I assume the co would want you to look at: favourable recent annualised EBITDAs (£40M per year), a ~£30M payback naturally drops out
Second, last, those multiples. Of course the assumptions are just my stab at torturing the numbers but all told, RR doesn't seem too bad. Worst case, waste of time perhaps and could think of worse places to start from you wanted a takeout or an outside shot at multibagger

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with HRouge

HRouge Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

More from @hareng_rouge

23 Sep
What does Sneller see to get such sudden FOMO for the old zombie that is Iofina #IOF? If you recall the name, it should produce revulsion but a few things have changed and there's a chance it may be about to make some money. ImageImage
IOF produces Iodine in the US via O&G brine. Iodine is a beneficiary of industrial recovery generally and covid specifically - the largest use is used as x-ray contrast which may benefit demand from catch up on delayed hospital treatment.

And because it's 2021, inevitably: Image
Production is trapped on the wrong side of the Pacific: the two major production centres are Japan and Chile - so you have the obvious logistics issues for both and potentially politics for the latter.
Read 12 tweets
20 Aug
I think it's worth revisiting Aquis #AQX here in light of a couple of data points that have since come out.

There are three main parts to the co: a stock exchange (AQSE); a tech licencing biz and their multilateral trading facility (AQXE) - it's this last one I want to look at.
First is the RNS from earlier this month announcing their MTF (investopedia.com/terms/m/multil…) had achieved 6.2% market share. Across the €53.6B traded on AQXE in July, this came out to €1.7B a day.

Those 6.2% and €1.7B are quite significant numbers and I'll come back to them later Image
In the period since the beginning of 2018 market share has risen from 1.72% to that 6.2% above. Here's how that value traded looks. Image
Read 15 tweets
10 Jun
Someone else has also since mentioned $JAKK to me - it's a (shitco) toy maker, similar to Character Group #CCT in the UK. CC's tweet mentions the refi, he has a point - I think there may be something here to play for, perhaps towards a double or so before the end of the year.
Company has cash of $80M + new debt of $99M (pink) repays difference on prior debt of $129M with cash on hand (green) so $50M cash + debt $99M

6,395 shares at $10.6, converts at $5.65 (purple) into $18.9M (blue) so + 3,345 shares = 9,740 / $103 cap & $20M prefs (grey) $172M EV
As you can see it's highly seasonal into Q3. Mgmt mentioned in the last (Q1) call that inventories are low. Typically they would be about $20M higher than here in Q2, so if we penalise the cash in the EV by that amount to account for inventory build we're at $192M
Read 12 tweets
4 Mar
Over the next decade or so, Transense #TRT will receive royalties on 6000+ of $GE's military helicopter engines and on many Bridgestone mining tires

Simple order of magnitude numbers suggest that the current cap of £12M may be undervaluing these cashflows quite substantially
It's not a complicated co but there are four parts to this. To help keep track, I'll deal with them in the following order:

1. Bridgestone (discounted 0.5x-1.5x+ cap)
2. Helis (anywhere from undiscounted 1x-10x cap)
3. Free optionalities
4. Tire probes (modest percentage of cap)
TRT makes advanced sensors.

On the Bridgestone side of things, the sensors monitor all aspects of super-large mining trucks' tire condition and provide geofencing and advanced capabilities for. Beyond likely cashflows the optionality here is to expand within the B'Stone range.
Read 25 tweets
22 Feb
Unfortunately this involves banks, turnarounds and LendingClub $LC but I think something potentially quite interesting may be happening here, due to this acquisition:
When I mentioned to Munger and Buffett the other day that I was reading up on LendingClub this was the reaction - and they're not too wrong: LC is crap
However, the business model is a little different these days and if my guess is right, it may all end up becoming little more than a vestigial artifact, like Chamath's legs

Where things stand now is that it's no longer so much a P2P lender.
Read 18 tweets
26 Jan
For a long time I thought computational drug modelling really had only one listed company: $SLP

Turns out maybe not: Physiomics #PYC could be a decent candidate for a comp.

Growth is inflecting, it has optionalities and thanks to AIM obscurity it's on a fwd EV/Sales of 6.5x
I first bought $SLP in April 2013. I mention this to make the point that was long before the current bubble in futuristic healthcare stocks, or before SaaS was a thing, this was already a punishingly expensive sector.

Here are the multiples you would've seen back then
Now, $SLP and #PYC are similar but not the same.

SLP was pure software to model drug absorption, sold on licence. It had incredible margins but slow, steady growth. In 2013 it did $10M in revs and in the most recent like-for-like split, FY19, it did $20: ~+10% a year or so
Read 13 tweets

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!

:(